Serina Therapeutics advances its wearable Parkinson's therapy trial to a second dosing stage

An early stage clinical trial evaluating a novel wearable therapy known as SER 252 has cleared its first major hurdle, allowing researchers to move forward to a higher dosing group. Following a review of initial safety data, an independent safety monitoring committee recommended that the study progress to its second cohort of participants. The treatment, developed by biotechnology company Serina Therapeutics, focuses on apomorphine, an established medication capable of easing motor symptoms when standard levodopa wears off. While apomorphine works by stimulating dopamine receptors in the brain, traditional continuous delivery methods usually demand cumbersome infusion pumps or frequent needle injections throughout the day. To address this hassle, SER 252 pairs a long acting formulation of the drug with a compact wearable device called Enfuse, which sticks to the skin and delivers the therapy steadily without tethering the user to heavy equipment. During the first stage of the Phase 1b trial, eight volunteers experiencing motor fluctuations received the lowest tested dose. To see how well the treatment performed on its own, participants were briefly guided off their usual background medications. The preliminary findings revealed that the medicine stayed in the system at a steady, prolonged level as intended. At the same time, clinicians observed sustained windows of improved movement in individual participants, while the therapy remained well tolerated. These initial observations provide an encouraging signal that steady, continuous dopaminergic stimulation can be achieved through a simpler wearable setup. For people who spend years navigating unpredictable periods where movement suddenly becomes difficult, finding smoother symptom control without heavy physical kit represents a significant step forward. The trial is continuing recruitment across clinical sites in the United States and Australia, with plans to expand into South Korea and Taiwan. Researchers will now test higher doses across successive groups of volunteers to pinpoint the safest and most effective amount. Serina Therapeutics aims to release top line findings from this single ascending dose phase of the study in the first half of 2027.